[go: up one dir, main page]

MX2014010494A - Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina. - Google Patents

Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.

Info

Publication number
MX2014010494A
MX2014010494A MX2014010494A MX2014010494A MX2014010494A MX 2014010494 A MX2014010494 A MX 2014010494A MX 2014010494 A MX2014010494 A MX 2014010494A MX 2014010494 A MX2014010494 A MX 2014010494A MX 2014010494 A MX2014010494 A MX 2014010494A
Authority
MX
Mexico
Prior art keywords
pyrazolo
triazine derivatives
diseases
inhinitors
dependent kinase
Prior art date
Application number
MX2014010494A
Other languages
English (en)
Other versions
MX347359B (es
Inventor
Jan Eickhoff
Gunther Zischinsky
Uwe Koch
Original Assignee
Lead Discovery Center Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Discovery Center Gmbh filed Critical Lead Discovery Center Gmbh
Publication of MX2014010494A publication Critical patent/MX2014010494A/es
Publication of MX347359B publication Critical patent/MX347359B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)

Abstract

La presente invención se refiere a derivados de pirazolo[1,5-a] [1,3,5] triazina y/o sales farmacéuticamente aceptables de los mismos; el uso de estos derivados como agentes farmacéuticamente activos, especialmente para la profilaxis y/o tratamiento de enfermedades infecciosas, incluidas las enfermedades oportunistas, enfermedades inmunológicas, enfermedades autoinmunes, enfermedades cardiovasculares, enfermedades proliferativas celulares, inflamación, disfunción eréctil y accidente cerebrovascular; y composiciones farmacéuticas que contienen al menos uno de dichos derivados de pirazolo[1,5-a] [1,3,5] triazina y/o sales farmacéuticamente aceptables de los mismos. Además, la presente invención se refiere al uso de dichos derivados de pirazolo [1,5-a] [1,3,5] triazina como inhibidores de una proteína cinasa.
MX2014010494A 2012-03-01 2013-03-01 Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina. MX347359B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12157751.4A EP2634190A1 (en) 2012-03-01 2012-03-01 Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
PCT/EP2013/054224 WO2013128028A1 (en) 2012-03-01 2013-03-01 Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhinitors

Publications (2)

Publication Number Publication Date
MX2014010494A true MX2014010494A (es) 2015-04-08
MX347359B MX347359B (es) 2017-04-06

Family

ID=47757629

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010494A MX347359B (es) 2012-03-01 2013-03-01 Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.

Country Status (17)

Country Link
US (1) US9567345B2 (es)
EP (2) EP2634190A1 (es)
JP (1) JP6182549B2 (es)
KR (1) KR101821452B1 (es)
CN (1) CN104350054B (es)
AU (1) AU2013224848B2 (es)
BR (1) BR112014021189B1 (es)
CA (1) CA2865946C (es)
DK (1) DK2820020T3 (es)
ES (1) ES2583231T3 (es)
HU (1) HUE029264T2 (es)
IL (1) IL234183A (es)
MX (1) MX347359B (es)
RU (1) RU2645347C2 (es)
SG (1) SG11201405129RA (es)
WO (1) WO2013128028A1 (es)
ZA (1) ZA201406078B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) * 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
ES2702951T3 (es) 2014-04-04 2019-03-06 Syros Pharmaceuticals Inc Inhibidores de quinasas dependientes de ciclina 7 (cdk7)
WO2015154022A1 (en) * 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP6690543B2 (ja) 2014-10-31 2020-04-28 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物
WO2016142855A2 (en) 2015-03-09 2016-09-15 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
EP3309163A4 (en) 2015-06-15 2019-01-09 UBE Industries, Ltd. SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
AU2016284638B2 (en) * 2015-06-24 2020-01-23 Curovir Ab Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина
CN106432249B (zh) * 2016-09-30 2018-12-04 陕西科技大学 一类吡咯并[2，1-f][1，2，4]三嗪母核化合物的合成及其医药用途
US11345705B2 (en) 2017-08-09 2022-05-31 Sanford Burnham Prebys Medical Discovery Institute Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists
GB201715194D0 (en) 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
US11649238B2 (en) * 2018-01-17 2023-05-16 Glaxosmithkline Intellectual Property Development Limited Substituted pyrazolo[1,5-a]pyrimidines as PI4K inhibitors
IL299105B2 (en) * 2018-04-11 2024-02-01 Lead Discovery Center Gmbh Pharmacologically active history of pyrazolo-trizine and/or pyrazolo-pyrimidine
MX2020010675A (es) * 2018-04-11 2020-10-28 Qurient Co Ltd Derivados de pirazolo-triazina y/o pirazolo-pirimidina como inhibidor selectivo de cinasa dependiente de ciclina.
US11517568B2 (en) 2018-09-12 2022-12-06 The Governing Council Of The University Of Toronto Compounds and methods for treating nematode infections
US12022832B2 (en) 2018-09-12 2024-07-02 The Governing Council Of The University Of Toronto Compounds and methods for treating nematode infections
KR20210118812A (ko) 2018-11-01 2021-10-01 사이로스 파마수티컬스, 인크. 시클린-의존성 키나제 7 (cdk7)의 억제제
EP3885347B1 (en) 2018-11-14 2023-11-22 UBE Corporation Dihydropyrrolopyrazole derivative
CN110101703B (zh) * 2019-05-06 2021-06-11 暨南大学 Cdk7抑制剂在制备溃疡性结肠炎或结肠癌药物的应用
RU2713152C1 (ru) * 2019-08-30 2020-02-04 Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения хронической аллергической крапивницы на фоне описторхоза
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
CN110950871B (zh) * 2019-12-25 2022-05-17 陕西师范大学 2-取代-4-芳氨基吡唑并三嗪衍生物及制备抗肿瘤药物的应用
EP4263554A1 (en) * 2020-12-21 2023-10-25 JANSSEN Pharmaceutica NV Tricyclic pyrimidines as cyclin-dependent kinase 7 (cdk7) inhibitors
WO2022182918A1 (en) * 2021-02-25 2022-09-01 Icahn School Of Medicine At Mount Sinai Methods for inhibiting inflammation and progression of atherosclerotic plaques and cardiovascular events in patients with cerebro- and cardio-vascular disease
JP2024509864A (ja) * 2021-03-09 2024-03-05 ヤンセン ファーマシューティカ エヌ．ベー． サイクリン依存性キナーゼ７（ｃｄｋ７）阻害剤としての三環式ピリジン
US20250042903A1 (en) * 2021-06-17 2025-02-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Triazine inhibitors of cyclin-dependent kinases
WO2023001061A1 (en) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Cdk7 selective inhibitors as anticancer agents
US20240327397A1 (en) 2021-07-29 2024-10-03 Syngenta Crop Protection Ag Pesticidally Active Fused Bicyclic Heteroaromatic Compounds
EP4436970A1 (en) * 2021-11-23 2024-10-02 Origenis GmbH Pyrazolotriazine derivatives useful as cdk9 inhibitors
CN114181217B (zh) * 2022-01-10 2022-12-27 陕西师范大学 吡唑并[1,5-a][1,3,5]三嗪衍生物及其盐和在制备抗癌药物中的应用
US20250205242A1 (en) * 2022-03-18 2025-06-26 Qurient Co., Ltd. Cdk7 inhibitors for antiviral treatment
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores
NZ513371A (en) * 1999-02-01 2003-08-29 Cv Therapeutics Inc 2,6,9 trisubstituted purine inhibitors of cyclin dependant kinase 2 and IkappaB-alpha
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
TW200536536A (en) 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
FR2943058B1 (fr) * 2009-03-11 2011-06-03 Centre Nat Rech Scient Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
CZ302711B6 (cs) * 2009-06-03 2011-09-14 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující

Also Published As

Publication number Publication date
KR20140131994A (ko) 2014-11-14
EP2820020B1 (en) 2016-04-06
BR112014021189B1 (pt) 2022-08-16
ZA201406078B (en) 2016-08-31
JP6182549B2 (ja) 2017-08-16
HK1206014A1 (en) 2015-12-31
IL234183A (en) 2016-11-30
DK2820020T3 (en) 2016-07-04
EP2820020A1 (en) 2015-01-07
WO2013128028A8 (en) 2014-10-02
US9567345B2 (en) 2017-02-14
AU2013224848A1 (en) 2014-08-28
CN104350054B (zh) 2017-06-13
SG11201405129RA (en) 2014-09-26
KR101821452B1 (ko) 2018-01-23
CN104350054A (zh) 2015-02-11
RU2014139705A (ru) 2016-04-20
MX347359B (es) 2017-04-06
EP2634190A1 (en) 2013-09-04
HUE029264T2 (en) 2017-02-28
AU2013224848B2 (en) 2017-06-29
WO2013128028A1 (en) 2013-09-06
ES2583231T3 (es) 2016-09-19
BR112014021189A2 (es) 2017-06-20
RU2645347C2 (ru) 2018-02-21
CA2865946C (en) 2020-01-21
CA2865946A1 (en) 2013-09-06
US20150018329A1 (en) 2015-01-15
JP2015511952A (ja) 2015-04-23

Similar Documents

Publication Publication Date Title
MX347359B (es) Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina.
MX2012010966A (es) Derivados de triazina disustituidos farmaceuticamente activos.
AR131260A2 (es) Compuestos para tratar atrofia muscular espinal
MX2015010858A (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
NZ751418A (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
MY199647A (en) Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
MX375353B (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MD4735B1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
MY179509A (en) Piperazine derivatives having multimodal activity against pain
MY177365A (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
IL268923A (en) History of alicyclic-converted pyrazolo[5,1-a]pyrimidine pharmacological activity
IL246034B (en) History of [1,2,4]triazolo[1,5-a]pyrimidine as protozoan proteasome inhibitors for the treatment of parasitic diseases such as Jericho
MX367772B (es) Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
MX2015011588A (es) Tratamiento de combinacion.
TN2016000557A1 (en) Pharmaceutical dosage forms
BR112015025033A2 (pt) prodrogas de inibidores da pde-5 do tipo pirimidina bicíclico substituídas
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора

Legal Events

Date Code Title Description
FG Grant or registration